BACKGROUND: Disease recurrence in patients with acute myeloid leukemia may be partially explained by the escape of leukemic blasts from CD4(+) T-cell recognition. The current study investigates the role of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clinical and functional impact of the class II-associated invariant chain peptide (CLIP). DESIGN AND METHODS: The levels of expression of CLIP and HLA-DR on blood and bone marrow samples from 207 patients with acute myeloid leukemia were correlated with clinical outcome. Irradiated CLIP(-) and CLIP(+) leukemic blasts were compared for their ability to induce CD4(+) T cells during mixed leukocyte reactions. To discriminate between these blasts, we down-modulated CLIP expression on myeloid leukemic cell lines by RNA interference of the invariant chain, a chaperone protein critically involved in HLA-DR processing, and performed flow cytometric sorting for their isolation from primary acute myeloid leukemia samples. RESULTS: We found that patients with leukemic blasts characterized by a high amount of HLA-DR occupied by CLIP (relative amount of CLIP) had a significantly shortened disease-free survival. The clear reductions in amount of HLA-DR occupied by CLIP on blasts of the THP-1 and Kasumi-1 myeloid leukemic cell lines after treatment with invariant chain short interfering RNA resulted in enhanced rates of allogeneic CD4(+) T-cell proliferation. Similar findings were obtained in an autologous setting, in which there were strong increases in proliferation of remission CD4(+) T cells stimulated with CLIP(-)-sorted leukemic blasts from HLA-DR(+) acute myeloid leukemia patients, in contrast to CLIP(+)-sorted leukemic blasts from the same patients. CONCLUSIONS: These data highlight the relevance of CLIP expression on leukemic blasts and the potential of CLIP as a target for immunomodulatory strategies to enhance HLA class II antigen presentation and CD4(+) T-cell reactivity in acute myeloid leukemia.
BACKGROUND: Disease recurrence in patients with acute myeloid leukemia may be partially explained by the escape of leukemic blasts from CD4(+) T-cell recognition. The current study investigates the role of aberrant HLA class II antigen presentation on leukemic blasts by determining both the clinical and functional impact of the class II-associated invariant chain peptide (CLIP). DESIGN AND METHODS: The levels of expression of CLIP and HLA-DR on blood and bone marrow samples from 207 patients with acute myeloid leukemia were correlated with clinical outcome. Irradiated CLIP(-) and CLIP(+) leukemic blasts were compared for their ability to induce CD4(+) T cells during mixed leukocyte reactions. To discriminate between these blasts, we down-modulated CLIP expression on myeloid leukemic cell lines by RNA interference of the invariant chain, a chaperone protein critically involved in HLA-DR processing, and performed flow cytometric sorting for their isolation from primary acute myeloid leukemia samples. RESULTS: We found that patients with leukemic blasts characterized by a high amount of HLA-DR occupied by CLIP (relative amount of CLIP) had a significantly shortened disease-free survival. The clear reductions in amount of HLA-DR occupied by CLIP on blasts of the THP-1 and Kasumi-1 myeloid leukemic cell lines after treatment with invariant chain short interfering RNA resulted in enhanced rates of allogeneic CD4(+) T-cell proliferation. Similar findings were obtained in an autologous setting, in which there were strong increases in proliferation of remission CD4(+) T cells stimulated with CLIP(-)-sorted leukemic blasts from HLA-DR(+) acute myeloid leukemiapatients, in contrast to CLIP(+)-sorted leukemic blasts from the same patients. CONCLUSIONS: These data highlight the relevance of CLIP expression on leukemic blasts and the potential of CLIP as a target for immunomodulatory strategies to enhance HLA class II antigen presentation and CD4(+) T-cell reactivity in acute myeloid leukemia.
Authors: V Lotteau; L Teyton; A Peleraux; T Nilsson; L Karlsson; S L Schmid; V Quaranta; P A Peterson Journal: Nature Date: 1990-12-13 Impact factor: 49.962
Authors: J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan Journal: Ann Intern Med Date: 1985-10 Impact factor: 25.391
Authors: Marvin M van Luijn; Theresia M Westers; Martine E D Chamuleau; S Marieke van Ham; Gert J Ossenkoppele; Arjan A van de Loosdrecht Journal: Am J Pathol Date: 2011-09-09 Impact factor: 4.307
Authors: Aleksandra Wroblewska; Simon D van Haren; Eszter Herczenik; Paul Kaijen; Aleksandra Ruminska; Sheng-Yu Jin; X Long Zheng; Maartje van den Biggelaar; Anja ten Brinke; Alexander B Meijer; Jan Voorberg Journal: Blood Date: 2012-04-12 Impact factor: 22.113
Authors: Marvin M van Luijn; Martine E D Chamuleau; Maaike E Ressing; Emmanuel J Wiertz; Suzanne Ostrand-Rosenberg; Yuri Souwer; Adri Zevenbergen; Gert J Ossenkoppele; Arjan A van de Loosdrecht; S Marieke van Ham Journal: Cancer Immunol Immunother Date: 2010-09-05 Impact factor: 6.968
Authors: Willemijn van den Ancker; Marvin M van Luijn; Jurjen M Ruben; Theresia M Westers; Hetty J Bontkes; Gert J Ossenkoppele; Tanja D de Gruijl; Arjan A van de Loosdrecht Journal: Cancer Immunol Immunother Date: 2010-09-22 Impact factor: 6.968
Authors: Marvin M van Luijn; Arjan A van de Loosdrecht; Margit H Lampen; Peter A van Veelen; Adri Zevenbergen; Michel G D Kester; Arnoud H de Ru; Gert J Ossenkoppele; Thorbald van Hall; S Marieke van Ham Journal: PLoS One Date: 2012-04-26 Impact factor: 3.240